IJMPCERO  Vol.4 No.2 , May 2015
Proton Therapy Results in the Treatment of Hepatocellular Carcinoma According to the Barcelona-Clinic Liver Cancer (BCLC) Staging System
ABSTRACT
Proton therapy represents the most advanced form of radiotherapy currently available. Hepato-cellular carcinoma (HCC) has been extensively treated with proton therapy since 1983 with en-couraging results in terms of effectiveness and safety, as reported in recent research articles, systematic reviews and meta-analyses. In this report, we summarized for the first time the results of proton therapy treatment for HCC according with respect to the Barcelona Clinic Liver Cancer Staging System, the most adopted classification system for HCC which provides information on both prognostic prediction and treatment allocation.

Cite this paper
Dionisi, F. and Amichetti, M. (2015) Proton Therapy Results in the Treatment of Hepatocellular Carcinoma According to the Barcelona-Clinic Liver Cancer (BCLC) Staging System. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 4, 96-103. doi: 10.4236/ijmpcero.2015.42013.
References
[1]   Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2013) Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. International Agency for Research on Cancer, France.
http://globocan.iarc.fr

[2]   Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J. and Cronin, K.A., Eds. (2013) SEER Cancer Statistics Review, 1975-2011. National Cancer Institute, Bethesda.
http://seer.cancer.gov/csr/1975_2011/

[3]   Llovet, J.M., Brú, C. and Bruix, J. (1999) Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Seminars in Liver Disease, 19, 329-338.
http://dx.doi.org/10.1055/s-2007-1007122

[4]   NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline) Hepatobiliary Cancers Version.
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

[5]   Korean Liver Cancer Study Group and National Cancer Center, Korea (2009) [Practice Guidelines for Management of Hepatocellular Carcinoma 2009]. Korean Journal of Hepatology, 15, 391-423.

[6]   (2012) EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. European Journal of Cancer, 48, 599-641.

[7]   Bujold, A., Massey, C.A., Kim, J.J., Brierley, J., Cho, C., Wong, R.K.S., et al. (2013) Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 31, 1631-1639.
http://dx.doi.org/10.1200/JCO.2012.44.1659

[8]   Méndez Romero, A., Wunderink, W., Hussain, S.M., De Pooter, J.A., Heijmen, B.J.M., Nowak, P.C.J.M., et al. (2006) Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors: A Single Institution Phase i-ii Study. Acta Oncologica (Stockholm, Sweden), 45, 831-837.
http://dx.doi.org/10.1080/02841860600897934

[9]   Wilson, R.R. (1946) Radiological Use of Fast Protons. Radiology, 47, 487-491.
http://dx.doi.org/10.1148/47.5.487

[10]   Dawson, L.A., Kavanagh, B.D., Paulino, A.C., Das, S.K., Miften, M., Li, X.A., et al. (2010) Radiation-Associated Kidney Injury. International Journal of Radiation Oncology*Biology* Physics, 76, S108-S115.
http://dx.doi.org/10.1016/j.ijrobp.2009.02.089

[11]   Particle Therapy Cooperative Group (PTCOG). http://ptcog.web.psi.ch/ptcentres.html

[12]   Forner, A., Llovet, J.M. and Bruix, J. (2012) Hepatocellular Carcinoma. The Lancet, 379, 1245-1255.
http://dx.doi.org/10.1016/S0140-6736(11)61347-0

[13]   Bruix, J. and Sherman, M. (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology, 53, 1020-1022.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084991/

[14]   Chiba, T., Tokuuye, K., Matsuzaki, Y., Sugahara, S., Chuganji, Y., Kagei, K., et al. (2005) Proton Beam Therapy for Hepatocellular Carcinoma: A Retrospective Review of 162 Patients. Clinical Cancer Research, 11, 3799-3805.
http://dx.doi.org/10.1158/1078-0432.CCR-04-1350

[15]   Komatsu, S., Fukumoto, T., Demizu, Y., Miyawaki, D., Terashima, K., Sasaki, R., et al. (2011) Clinical Results and Risk Factors of Proton and Carbon Ion Therapy for Hepatocellular Carcinoma. Cancer, 117, 4890-4904.
http://dx.doi.org/10.1002/cncr.26134

[16]   Kim, T.H., Park, J.-W., Kim, Y.-J., Kim, B.H., Woo, S.M., Moon, S.H., et al. (2014) Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma. Cancer Research and Treatment, 47, 34-45.

[17]   Llovet, J.M. and Bruix, J. (2003) Systematic Review of Randomized Trials for Unresectable Hepatocellular Carcinoma: Chemoembolization Improves Survival. Hepatology, 37, 429-442.
http://dx.doi.org/10.1053/jhep.2003.50047

[18]   Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390.
http://dx.doi.org/10.1056/NEJMoa0708857

[19]   Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J.S., et al. (2009) Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Oncology, 10, 25-34.
http://dx.doi.org/10.1016/S1470-2045(08)70285-7

[20]   Hawkins, M.A. and Dawson, L.A. (2006) Radiation Therapy for Hepatocellular Carcinoma: From Palliation to Cure. Cancer, 106, 1653-1663.
http://www.ncbi.nlm.nih.gov/pubmed/16541431

[21]   Sugahara, S., Nakayama, H., Fukuda, K., Mizumoto, M., Tokita, M., Abei, M., et al. (2009) Proton-Beam Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis. Strahlentherapie und Onkologie, 185, 782-788.
http://dx.doi.org/10.1007/s00066-009-2020-x

[22]   Lee, S.U., Park, J.-W., Kim, T.H., Kim, Y.-J., Woo, S.M., Koh, Y.-H., et al. (2014) Effectiveness and Safety of Proton Beam Therapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Strahlentherapie und Onkologie, 190, 806-814.

[23]   Bush, D.A., Kayali, Z., Grove, R. and Slater, J.D. (2011) The Safety and Efficacy of High-Dose Proton Beam Radiotherapy for Hepatocellular Carcinoma: A Phase 2 Prospective Trial. Cancer, 117, 3053-3059.
http://dx.doi.org/10.1002/cncr.25809

[24]   Hata, M., Tokuuye, K., Sugahara, S., Fukumitsu, N., Hashimoto, T., Ohnishi, K., et al. (2006) Proton Beam Therapy for Hepatocellular Carcinoma Patients with Severe Cirrhosis. Strahlentherapie und Onkologie, 182, 713-720.
http://dx.doi.org/10.1007/s00066-006-1564-2

[25]   Dionisi, F., Widesott, L., Lorentini, S. and Amichetti, M. (2014) Is There a Role for Proton Therapy in the Treatment of Hepatocellular Carcinoma? A Systematic Review. Radiotherapy and Oncology, 111, 1-10.

[26]   Dionisi, F. and Ben-Josef, E. (2014) The Use of Proton Therapy in the Treatment of Gastrointestinal Cancers: Liver. Cancer Journal, 20, 371-377.
http://dx.doi.org/10.1097/PPO.0000000000000082

[27]   Qi, W.-X., Fu, S., Zhang, Q. and Guo, X.-M. (2014) Charged Particle Therapy versus Photon Therapy for Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Radiotherapy and Oncology, in press.

[28]   ASTRO Model Policies: Proton Beam Therapy [Internet] (2014).
https://www.astro.org/uploadedFiles/Main_Site/Practice_Management/Reimbursement/
ASTRO%20PBT%20Model%20Policy%20FINAL.pdf


 
 
Top